The effect of Liraglutide treatment on postprandial chylomicron and VLDLkinetics, liver fat and de novo lipogenesis. A single-center randomizedcontrolled study. - LIRA

Research Programs' Unit, Diabetes & Obesity, University of Helsinki0 个研究点开始时间: 2014年2月3日最近更新: 2014年4月14日

适应症

试验速览

暂无简介。

•Obese subjects with T2D and a large waist (waist > 88 cm in women and > 92 cm in men, BMI 27–40 kg/m2, triglycerides between 1.0 – 4.0 mmol/L and LDL < 4.5 mmol/l) treated with a lifestyle or metformin (any dose) (HbA1c 6.5-9% ) and aged 30 – 75 years will be included. Subjects may or may not use statins
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

•?Type 1 diabetes
•?Apo E2/2 phenotype
•?ALT/AST > 3x ULN
•?GFR < 60 ml/min, clinically significant TSH outside normal range
•?Lipid-lowering drugs other than statins within 6 months
•?Treatment with pioglitazone, insulin, sulphonylureas, gliptines, glinides, SGLT-2 inhibitors or thiazide diuretics (at a dose of > 25 mg / day) within 6 months
•?Blood pressure > 160 mmHg systolic and/or > 105 diastolic
•?History of pancreatitis or stomach / other major bleeding, thyroid neoplasia, persistent hypothyroidism or persistent hyperthyroidism
•?Any medical condition that puts the patient in the risk of dehydration
•?Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
•?Females of childbearing potential who are not using adequate contraceptive methods
•?Subjects who have experienced side-effects previously from GLP-1 agonists
•?Non-compliance or withdrawal of consent

发起方

Research Programs' Unit, Diabetes & Obesity, University of Helsinki